Press Enter to search · Esc to close
Semaglutide's clinical footprint is widening fast — new data hint at off-target wins, real-world rescues, and a sharpening list of who should pause before the pen.
A new phase 3 trial shows a once-daily pill can deliver meaningful weight loss without a needle — and that small detail could change who actually gets treated.
The first non-peptide oral GLP-1 has real bioavailability data, prescriptions to women of reproductive age are climbing fast, and social-media ads are quietly rewriting how the public reads the science.
A fresh post hoc dive into EXSCEL says the cardiovascular payoff from a once-weekly GLP-1 isn't fully explained by better A1c, blood pressure, or bodyweight. Something else is doing work.
Three new clinical analyses cut through the semaglutide and tirzepatide hype — quantifying real-world weight loss at one year, the muscle question lifters keep asking, and what happens when patients head into the OR.
A new review reframes Alzheimer's risk around peripheral insulin resistance — not blood sugar itself — and points to tiny cellular couriers as possible carriers of metabolic damage to the brain.
A wave of head-to-head trials and a biased-agonist newcomer show the GLP-1 class is fragmenting into distinct molecules with measurably different profiles.
A new flow-NMR study cracks open how a marketed GLP-1 drug quietly rearranges itself in solution — and why that matters for the next generation of injectables busy men will actually use.
A post-hoc analysis of a randomized trial found semaglutide reduced multiple DNA-methylation aging clocks. It's early, narrow, and genuinely intriguing.
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.